Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bandwidth Q2 EPS $(0.04) Beats $(0.06) Estimate, Sales $136.00M Beat $133.66M Estimate

Bandwidth (NASDAQ:BAND) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 112.5 percent decrease over earnings of $0.32 per share from the
byMichael Horton
August 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Bandwidth (NASDAQ:BAND) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 112.5 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $136.00 million which beat the analyst consensus estimate of $133.66 million by 1.75 percent. This is a 12.72 percent increase over sales of $120.66 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Reported Farxiga Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients With Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial

By Charles Gross
August 27, 12:47 PM
Detailed results from the DELIVER Phase III trial showed AstraZeneca's Farxiga (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo.

AZN